{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:27:47Z","timestamp":1786512467397,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroendocrine carcinomas (NECs) are rare and highly aggressive tumors, characterized by a dismal prognosis. Their underlying biology remains insufficiently understood, highlighting an urgent need for the identification of disease markers to enhance diagnostic and prognostic assessments, as well as to identify potential druggable targets. DLL3, an inhibitory regulator of the Notch signalling pathway, has emerged as a promising candidate in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We investigated DLL3 prevalence and pattern of expression in immunohistochemistry in NECs from multiple anatomical sites, with a focus on lung and gastroenteropancreatic (GEP) neoplasms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DLL3 was found to be highly expressed in 68.8% of NECs overall, with the highest prevalence observed in GEP-NECs (85.7%). Immunohistochemical analysis revealed predominantly cytoplasmic localization, with a dot-like staining pattern particularly evident in gastrointestinal cases, suggestive of potential localization in neurosecretory granules. DLL3 levels did not significantly correlate with tumor proliferation index nor with overall survival. A correlation with chromogranin A expression was found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Given its high prevalence in extrapulmonary NECs, particularly those of GEP origin, it may have potential as a disease marker and therapeutic target in a clinical context where effective options are currently limited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1864568","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:39:05Z","timestamp":1786509545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["DLL3 expression in neuroendocrine carcinomas: a comparative analysis across tumor origins"],"prefix":"10.3389","volume":"17","author":[{"given":"Chiara","family":"Calabrese","sequence":"first","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Dellavalle","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Spadazzi","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sable","sequence":"additional","affiliation":[{"name":"Amgen, Inc.","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"French","sequence":"additional","affiliation":[{"name":"Amgen, Inc.","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Isse","sequence":"additional","affiliation":[{"name":"Amgen, Inc.","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushboo","family":"Sharma","sequence":"additional","affiliation":[{"name":"Amgen, Inc.","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Laino","sequence":"additional","affiliation":[{"name":"Amgen, Inc.","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Fasano","sequence":"additional","affiliation":[{"name":"Amgen, Inc.","place":["Thousand Oaks, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Tumedei","sequence":"additional","affiliation":[{"name":"Advanced Cellular Therapies and Rare Tumors Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pieri","sequence":"additional","affiliation":[{"name":"Pathology Unit, \u201cMorgagni-Pierantoni\u201d Hospital","place":["Forl\u00ec, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Ranallo","sequence":"additional","affiliation":[{"name":"Clinical and Experimental Oncology, Immunotherapy, Rare Cancers and Biological Resource Center, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Foca","sequence":"additional","affiliation":[{"name":"Biostatistics and Clinical Trial Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola FC, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"De Vita","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Miserocchi","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Cocchi","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vanni","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Gabellone","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oneda","family":"Cani","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Sbanchi","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Departmental Faculty of Medicine, UniCamillus-Saint Camillus International University of Health and Medical Sciences","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Liverani","sequence":"additional","affiliation":[{"name":"Preclinic and Osteoncology Unit, Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) \u201cDino Amadori\u201d","place":["Meldola, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155138","article-title":"A comprehensive review on neuroendocrine neoplasms: Presentation, pathophysiology and management","volume":"12","author":"Sultana","year":"2023","journal-title":"J Clin Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1093\/oncolo\/oyab039","article-title":"Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas","volume":"27","author":"Dasari","year":"2022","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231156870","article-title":"Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: A review","volume":"15","author":"Robinson","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247715","article-title":"Extrapulmonary neuroendocrine carcinomas: Current management and future perspectives","volume":"12","author":"Stumpo","year":"2023","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164152","article-title":"Is the morphological subtype of extra-pulmonary neuroendocrine carcinoma clinically relevant","volume":"13","author":"Frizziero","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00428-020-03015-z","article-title":"Morphologic and molecular classification of lung neuroendocrine neoplasms","volume":"478","author":"Metovic","year":"2021","journal-title":"Virchows Arch"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-022-01435-8","article-title":"Update from the 5th edition of the World Health Organization classification of head and neck tumors: Overview of the 2022 WHO classification of head and neck neuroendocrine neoplasms","volume":"16","author":"Mete","year":"2022","journal-title":"Head Neck Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-024-04006-0","article-title":"Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: An immunohistochemical study of 465 high-grade neuroendocrine neoplasms","volume":"486","author":"Kanaan","year":"2025","journal-title":"Virchows Arch"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122828","article-title":"Enhancer of zeste homolog 2 (EZH2) is a marker of high-grade neuroendocrine neoplasia in gastroenteropancreatic and pulmonary tract and predicts poor prognosis","volume":"14","author":"Bremer","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn275","article-title":"Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors","volume":"100","author":"Modlin","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","article-title":"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): A randomised, multicentre, non-comparative, open-label, phase 2 trial","volume":"24","author":"Walter","year":"2023","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114129","article-title":"A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas","volume":"208","author":"Bongiovanni","year":"2024","journal-title":"Eur J Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00094","article-title":"Notch signaling in neuroendocrine tumors","volume":"6","author":"Crabtree","year":"2016","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-535","article-title":"Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors","volume":"12","author":"Kunnimalaiyaan","year":"2007","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114248","article-title":"Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer","volume":"159","author":"Zhang","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200702009","article-title":"Divergent functions and distinct localization of the Notch ligands DLL1 and DLL3 in vivo","volume":"178","author":"Geffers","year":"2007","journal-title":"J Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav0891","article-title":"Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer","volume":"11","author":"Puca","year":"2019","journal-title":"Sci Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0877","article-title":"Delta-like protein 3 expression and targeting in Merkel cell carcinoma","volume":"25","author":"Xie","year":"2020","journal-title":"Oncologist"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.10.010","article-title":"DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile","volume":"138","author":"Hermans","year":"2019","journal-title":"Lung Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.06.025","article-title":"Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment","volume":"135","author":"Messaritakis","year":"2019","journal-title":"Lung Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2346","article-title":"Clinical pharmacology profile of AMG 119, the first chimeric antigen receptor T (CAR-T) cell therapy targeting delta-like ligand 3 (DLL3), in patients with relapsed\/refractory small cell lung cancer (SCLC)","volume":"64","author":"Zhou","year":"2024","journal-title":"J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): A multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-020-09657-8","article-title":"Diagnostic and predictive role of DLL3 expression in gastroenteropancreatic neuroendocrine neoplasms","volume":"32","author":"Liverani","year":"2021","journal-title":"Endocr Pathol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000348832","article-title":"Improving the diagnosis and management of neuroendocrine tumors: Utilizing new advances in biomarker and molecular imaging science","volume":"98","author":"Giandomenico","year":"2013","journal-title":"Neuroendocrinology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: An emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14737140.2022.2071703","article-title":"Delta-like ligand 3 (DLL3): An attractive actionable target in tumors with neuroendocrine origin","volume":"22","author":"Ranallo","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S244860","article-title":"The role of DLLs in cancer: A novel therapeutic target","volume":"13","author":"Xiu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17040520","article-title":"Targeting DLL3: Innovative strategies for tumor treatment","volume":"17","author":"Wang","year":"2025","journal-title":"Pharmaceutics"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0501","article-title":"Expression patterns of DLL3 across neuroendocrine and non-neuroendocrine neoplasms reveal broad opportunities for therapeutic targeting","volume":"5","author":"Lozada","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-025-09854-3","article-title":"DLL3 expression in neuroendocrine carcinomas and neuroendocrine tumours: Insights from a multicentric cohort of 1294 pulmonary and extrapulmonary neuroendocrine neoplasms","volume":"36","author":"Schmitt","year":"2025","journal-title":"Endocr Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28660","article-title":"Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC","volume":"15","author":"Silva","year":"2024","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41698-024-00739-y","article-title":"Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms","volume":"8","author":"Serrano","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1038\/s41598-025-86237-y","article-title":"Exploring the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms and its potential diagnostic value","volume":"15","author":"Yin","year":"2025","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2018-0497-OA","article-title":"Delta-like protein 3 prevalence in small cell lung cancer and DLL3 (SP347) assay characteristics","volume":"143","author":"Huang","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14157","article-title":"Delta-like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine Malignancy","volume":"110","author":"Matsuo","year":"2019","journal-title":"Cancer Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.734901","article-title":"Delta-like protein 3 expression in paired chemonaive and chemorelapsed small cell lung cancer samples","volume":"8","author":"Kuempers","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B43","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: Results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1158\/2326-6074.io2026-lb-a003","article-title":"Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial","volume":"43","author":"Capdevila","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1864568\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:39:11Z","timestamp":1786509551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1864568\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":46,"alternative-id":["10.3389\/fendo.2026.1864568"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1864568","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1864568"}}